Leukemia: Clinical Trials

573 trials for Leukemia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

573 terminated. 573 Phase 2, 189 Phase 1, 12 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 2573Terminated 573
Phase 1189Terminated 189
Phase 312Terminated 12

Follow Leukemia: new trials by email Literature Review of Leukemia trials Research Report on Leukemia

Trials (filtered) newest first · largest first

All 573 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Multiple CAR-T Cell Therapy Targeting AML
CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells - Acute Myeloid Leukemia
Phase 1 / Phase 2TerminatedShenzhen Geno-Immune Medical Institute102025-08-012026-11-02
Combination CAR-T Cell Therapy Targeting Hematological Malignancies
4SCAR19 and 4SCAR22, 4SCAR19 and 4SCAR38, 4SCAR19 and 4SCAR20 - B-cell Malignancies
Phase 1 / Phase 2TerminatedShenzhen Geno-Immune Medical Institute1002025-08-012026-10-30
A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML
S227928, Venetoclax - Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)/AML
Phase 1 / Phase 2TerminatedServier Bio-Innovation LLC132025-02-252026-03-30
BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS
SOC + BSB-1001 Dose Escalation Cohort, SOC+BSB-1001 Expansion Dose - AML, Adult Recurrent, ALL, Recurrent, Adult
Phase 1 / Phase 2TerminatedBlueSphere Bio, Inc22025-02-042026-09-10
Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AML
Luveltamab tazevibulin - Acute Myeloid Leukemia (AML)
Phase 1 / Phase 2TerminatedSutro Biopharma, Inc.12024-12-042026-10-13
Acute Myeloid Leukemia Treated With With NETrin Abs in Combination With [AZACITIDINE + VENETOCLAX]
NP137, Azacitidine Injection, Venetoclax - Acute Myeloid Leukemia Refractory
Phase 1 / Phase 2TerminatedCentre Leon Berard12024-09-112025-02-20
A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies
SAR443579, venetoclax, azacitidine - Acute Myeloid Leukemia
Phase 1 / Phase 2TerminatedSanofi72024-08-132026-10-19
Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML
RVU120 - Acute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome
Phase 2TerminatedRyvu Therapeutics SA622024-01-232026-09-16
Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant
VCAR33 - Leukemia, Myeloid, Acute
Phase 1 / Phase 2TerminatedVor Biopharma382023-12-112025-07-29
Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes
KPT-8602, Inqovi, Bone marrow aspirate - Myelodysplastic Syndromes
Phase 1 / Phase 2TerminatedNational Cancer Institute (NCI)32023-11-142025-12-02
Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid Leukemia
Clofarabine, Fludarabine, Hematopoietic Cell Transplantation - Acute Myeloid Leukemia, Myelodysplastic Syndrome
Phase 2TerminatedFred Hutchinson Cancer Center232023-08-112026-08-06
A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia
GDX012, Chemotherapy Agents - Leukemia
Phase 1 / Phase 2TerminatedTakeda162023-07-112026-09-25
Selinexor、Venetoclax and Azactidine in the Treatment of ND AML Patients Who Are Not Eligible for Intense Chemotherapy
Selinexor, Venetoclax, Azacitidine - Acute Myeloid Leukemia, Adult
Phase 1 / Phase 2TerminatedInstitute of Hematology & Blood Diseases Hospital, China62023-05-052025-05-30
Decitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients Who Have Relapsed Acute Myeloid Leukemia After Donor Stem Cell Transplant
Venetoclax, Decitabine, Cedazuridine - Recurrent Acute Myeloid Leukemia
Phase 2TerminatedSanjay Mohan12023-04-132026-01-09
Phase II Study to Evaluate Safety and Efficacy of CB-103 With Venetoclax in Adolescent and Young Adult Patients With Relapsed/Refractory T-ALL or T-LBL
CB-103, Venetoclax - Leukemia, Lymphoblastic, Leukemia
Phase 2TerminatedM.D. Anderson Cancer Center22023-04-062025-11-26
A Study of Siremadlin Alone and in Combination With Donor Lymphocyte Infusion in Acute Myeloid Leukemia Post-allogeneic Stem Cell Transplant
Siremadlin - Acute Myeloid Leukemia, Allogeneic Stem Cell Transplantation
Phase 1 / Phase 2TerminatedNovartis Pharmaceuticals82023-02-232025-05-16
A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma
MS-553 - Relapsed or Refractory B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL)
Phase 1 / Phase 2TerminatedMingSight Pharmaceuticals, Inc82023-02-062024-07-18
Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML)
ZN-d5 ZN-c3, ZN-c3 - Acute Myeloid Leukemia (AML)
Phase 1 / Phase 2TerminatedK-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.402022-12-012024-09-19
Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With Venetoclax
Pirtobrutinib, Venetoclax - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Phase 1 / Phase 2TerminatedM.D. Anderson Cancer Center32022-11-162025-12-15
Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies
Brexucabtagene Autoleucel, Cyclophosphamide, Fludarabine - Relapsed/Refractory Waldenstrom Macroglobulinemia, Relapsed/Refractory Richter Transformation
Phase 2TerminatedKite, A Gilead Company192022-11-012026-03-10

Showing 20 of 573. Sign in to see all of them.

Narrower conditions

Leukemia, Myeloid, Acute (239)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (156)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (131)  ·  Myelodysplastic Syndromes (129)  ·  Lymphoma, Non-Hodgkin (80)  ·  Lymphoma (77)  ·  Leukemia, Myelogenous, Chronic, BCR-ABL Positive (72)  ·  Lymphoma, Large B-Cell, Diffuse (51)  ·  Lymphoma, Follicular (50)  ·  Multiple Myeloma (49)  ·  Recurrence (49)  ·  Lymphoma, Mantle-Cell (46)  ·  Hodgkin Disease (43)  ·  Burkitt Lymphoma (40)

Broader conditions

Hemic and Lymphatic Diseases (573)  ·  Neoplasms by Histologic Type (572)  ·  Hematologic Diseases (563)  ·  Neoplasms (553)  ·  Immune System Diseases (319)  ·  Immunoproliferative Disorders (315)  ·  Leukemia, Myeloid (311)  ·  Lymphatic Diseases (310)  ·  Lymphoproliferative Disorders (308)  ·  Pathological Conditions, Signs and Symptoms (291)  ·  Pathologic Processes (289)  ·  Disease Attributes (281)  ·  Leukemia, Lymphoid (275)  ·  Chronic Disease (251)

Interventions

Cyclophosphamide (67)  ·  Cytarabine (64)  ·  fludarabine phosphate (53)  ·  fludarabine (52)  ·  Rituximab (49)  ·  Azacitidine (39)  ·  Methotrexate (38)  ·  venetoclax (33)  ·  Busulfan (30)  ·  Whole-Body Irradiation (30)  ·  Filgrastim (28)  ·  Tacrolimus (28)  ·  Antilymphocyte Serum (25)  ·  Mycophenolic Acid (23)  ·  Granulocyte Colony-Stimulating Factor (22)

Sponsors

M.D. Anderson Cancer Center (72)  ·  National Cancer Institute (NCI) (30)  ·  Masonic Cancer Center, University of Minnesota (23)  ·  Fred Hutchinson Cancer Center (19)  ·  Gilead Sciences (10)  ·  Novartis Pharmaceuticals (9)  ·  OHSU Knight Cancer Institute (9)  ·  TG Therapeutics, Inc. (8)  ·  Washington University School of Medicine (8)  ·  H. Lee Moffitt Cancer Center and Research Institute (7)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (7)  ·  St. Jude Children's Research Hospital (7)  ·  Sanofi (6)  ·  Bristol-Myers Squibb (5)  ·  Emory University (5)

Countries

United States (468)  ·  France (52)  ·  Germany (45)  ·  Italy (43)  ·  Spain (38)  ·  Canada (32)  ·  United Kingdom (32)  ·  Australia (20)  ·  Belgium (20)  ·  Netherlands (20)  ·  South Korea (15)  ·  Poland (14)  ·  Austria (11)  ·  China (11)  ·  Czechia (10)

Top investigators

Courtney DiNardo, MD (5)  ·  Jorge Cortes, MD (5)  ·  Elias Jabbour (3)  ·  Guillermo Garcia-Manero, MD (3)  ·  Januario Castro, M.D. (3)  ·  Noelle Frey, MD (3)  ·  Srdan Verstovsek (3)  ·  Stephen Anthony, DO (3)

Results publications

PMID 35622074, PMID 26472751, PMID 28835440, PMID 30885996, PMID 31527168, PMID 34398557, PMID 41671463, PMID 12011123, PMID 16651647, PMID 17579184, PMID 19139736, PMID 19179301, PMID 19826119, PMID 20307284, PMID 21145590, PMID 21403127, PMID 21874061, PMID 22080968, PMID 22133771, PMID 22267607, PMID 22289993, PMID 22430088, PMID 22766223, PMID 22987312, PMID 23233571, PMID 23265768, PMID 23426279, PMID 23426943, PMID 23620574, PMID 23782682, PMID 23949430, PMID 24081577, PMID 24200998, PMID 24241210, PMID 24355079, PMID 24615776, PMID 24615777, PMID 24615778, PMID 24719405, PMID 24891274, PMID 24925211, PMID 24990615, PMID 25127392, PMID 25130401, PMID 25441108, PMID 25596730, PMID 25696919, PMID 25878120, PMID 25939707, PMID 26053664

NIH funding

P30CA015704 (10), 2018 (9), P30CA016672 (7), 2023 (5), P30CA015083 (5), 2009 (4), 2016 (4), 2019 (4), P01CA018029 (4), P50CA171963 (4), 2008 (3), 2014 (3), 2015 (3), 2017 (3), N01CM17003 (3)